Tucidinostat clinical trials
Also written Chidamide, Epidaza, HBI-8000 and CS055.
How each study uses tucidinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tucidinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
185 studies that test it; most in 2022 (30)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 16 |
| 2017 | 10 |
| 2018 | 9 |
| 2019 | 10 |
| 2020 | 12 |
| 2021 | 17 |
| 2022 | 30 |
| 2023 | 19 |
| 2024 | 24 |
| 2025 | 11 |
| 2026 | 20 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 166
Sun Yat-sen University (20) · Chinese PLA General Hospital (11) · Ruijin Hospital (11) · Chipscreen Biosciences, Ltd. (9) · The First Affiliated Hospital of Soochow University (8) · HUYABIO International, LLC. (7) · Peking Union Medical College Hospital (7) · Tianjin Medical University Cancer Institute and Hospital (6)
Often tested with
Tested in the same studies.
Azacitidine (14) · Sintilimab (13) · Venetoclax (11) · Toripalimab (6) · Golidocitinib (6) · Cytarabine (5) · Aclacinomycins (5) · Rituximab (5)
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Tucidinostat is the comparator. A study of two new drugs counts under both.
- 1Liposomal Mitoxantrone Hydrochloride · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · next primary completion Dec 2027
- 1Mitoxantrone · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · next primary completion Dec 2027
- 1Golidocitinib · Dizal Pharmaceuticals · next primary completion Nov 2027
Reaching primary completion within a year · 19, 1 in phase 3
Studies that test tucidinostat, phase 3 first.
- Sep 2027Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaPhase 3 · Chinese PLA General Hospital
- Dec 2026A Study of Chidamide With AZA in MRD Positive AML After TransplantNot applicable · Guangdong Provincial People's Hospital
- Dec 2026VAC Regimen for AML Patients Who Failed to Response to VA RegimenPhase 2 · The First Affiliated Hospital of Soochow University
- Dec 2026Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLPhase 2 · Guangdong Provincial People's Hospital
- Dec 2026Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Dec 2026Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AMLPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
- Feb 2027A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerPhase 2 · Peking University
- Mar 2027Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLPhase 2 · The First Affiliated Hospital with Nanjing Medical University
Studies
Open first, then newest update. How each study uses tucidinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 185
- Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07917624Written as Chidamide
- Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTCNot yet recruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07890506Written as chidamide+benmelstobart+nab-paclitaxel+SBRT
- Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT06947967Written as Tucidinostat
- Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07884708Written as Chidamide in combination with Lenalidomide and Rituximab (CR2)
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07159620Written as Chidamide
- A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) ExpressionRecruitingPhase 2Guangdong Association of Clinical TrialsNCT07412262Written as Chidamide in combination with Ivonescimab
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaRecruitingPhase 3Chinese PLA General HospitalNCT07514936Written as Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
- Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/LymphomaNot yet recruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT07774377Written as Chidamide
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingPhase 1/2Peking Union Medical College HospitalNCT07754890Written as Chidamide
- The Efficacy of CAPCT in Patients With PTCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07746245Written as Chidamide
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06570447Written as Chidamide
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07397832Written as Chidamide
- New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07706959Written as Zeprumetostat plus chidamide with CHOP
- Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)RecruitingPhase 2Great Novel Therapeutics Biotech & Medicals CorporationNCT05833724Written as Chidamide
- Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia RelapseRecruitingPhase 1/2Zhujiang HospitalNCT05270200Written as Chidamide
- Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AMLNot yet recruitingPhase 2Dongguan People's HospitalNCT07643636Written as Chidamide (Chi)+VAH
- Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRecruitingPhase 2Rong TaoNCT07507318Written as Chidamide
- A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIVNot yet recruitingPhase 1First Affiliated Hospital of Zhejiang UniversityNCT07635992Written as Ibalizumab Combined with Chidamide
- Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic SyndromesNot yet recruitingPhase 2Zhongshan Hospital (Xiamen), Fudan UniversityNCT07616336Written as Chidamide
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07601607Written as Chidamide
See all 185 studies that test tucidinostat →
Given beside what is tested · 10 — tucidinostat is usual care or a partner of the new treatment
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingPhase 2Ruijin HospitalNCT07380984Written as Chidamide
- QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06951997Written as Chidamide
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Chidamide
- Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorNot yet recruitingPhase 2Beijing 302 HospitalNCT06556862Written as Chidamide
- APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT05186012Written as Chidamide
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingPhase 1/2Ruijin HospitalNCT05559008Written as Tucidinostat
- Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingPhase 2Sun Yat-sen UniversityNCT04724239Written as Chidamide
- A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV ReservoirsCompletedPhase 2United BioPharmaNCT05056974Written as chidamide
- A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast CancerStatus unknownPhase 2Fudan UniversityNCT05438706Written as chidamide
- Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsStatus unknownPhase 2Peking UniversityNCT03617432Written as Chidamide
As the comparator · 2 — what is tested is compared with tucidinostat
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingPhase 3Dizal PharmaceuticalsNCT07234162Written as Chidamide
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLActive, not recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04668690Written as Chidamide
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered3
- Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaNov 4, 2026NCT07917624
- Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTCOct 22, 2026NCT07890506
- Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLOct 20, 2026NCT07884708
Codes
What other systems call tucidinostat · ClinicalTrials.gg INT005587
- MeSH (NLM) C547816N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideConfirmed NLM, Wikidata
- UNII (FDA) 87CIC980Y0TUCIDINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q19903814tucidinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97263TucidinostatOne source FDA
- DrugBank DB06334One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547816 | N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide | Confirmed NLM, Wikidata |
| UNII (FDA) | 87CIC980Y0 | TUCIDINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19903814 | tucidinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97263 | Tucidinostat | One source FDA |
| DrugBank | DB06334 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.